TSE:MDNA

Medicenna Therapeutics (MDNA) Stock Forecast, Price & News

C$0.77

-0.01 (-1.28%)

(As of 06/8/2023 ET)

Compare

Today's Range: C$0.77
▼
C$0.80
50-Day Range: C$0.72
▼
C$1.11
52-Week Range: C$0.54
▼
C$2.38

Volume: 2,510 shs
Average Volume: 22,190 shs
Market Capitalization: C$53.62 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: C$5.33

Profile Analyst Ratings Chart Competitors Insider Trades Headlines Social Media

About Medicenna Therapeutics (TSE:MDNA) Stock

Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase IIb clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.

Receive MDNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medicenna Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MDNA Stock News Headlines

April 19, 2023 | theglobeandmail.com

Closing Bell: Medicenna Therapeutics Corp up on Tuesday (MDNA)

April 18, 2023 | theglobeandmail.com

Closing Bell: Medicenna Therapeutics Corp up on Monday (MDNA)

June 8, 2023 | Altimetry (Ad)

Pentagon Consultant—Here's how Biden Wins Landslide Re-election

—but also hand Joe Biden a landslide re-election win. What would America look like if we slide further towards Socialism? Full story and 4 steps you can take,

April 8, 2023 | theglobeandmail.com

Closing Bell: Medicenna Therapeutics Corp down on Thursday (MDNA)

February 8, 2023 | finance.yahoo.com

Medicenna Therapeutics Corp. (NASDAQ:MDNA) Q3 2023 Earnings Call Transcript

February 6, 2023 | benzinga.com

Medicenna Therapeutics Earnings Preview

February 6, 2023 | benzinga.com

Earnings Preview For Medicenna Therapeutics

January 26, 2023 | finance.yahoo.com

Medicenna to Announce Third Quarter Fiscal 2023 Financial Results and Operational Highlights on Tuesday, February 7, 2023

June 8, 2023 | Behind the Markets (Ad)

BREAKING: Tiny biotech successfully treats blindness

There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.

November 10, 2022 | finance.yahoo.com

Medicenna Presents Updated Clinical Data from Dose Escalation Portion of Phase 1/2 ABILITY Study of MDNA11 at the SITC Annual Meeting

November 8, 2022 | finance.yahoo.com

Medicenna Therapeutics (TSE:MDNA) Is In A Good Position To Deliver On Growth Plans

November 3, 2022 | msn.com

Earnings Outlook For Medicenna Therapeutics

October 28, 2022 | finance.yahoo.com

Medicenna Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

October 6, 2022 | finance.yahoo.com

MDNA: Confirmed Partial Response in Pancreatic Cancer Patient…

October 5, 2022 | finance.yahoo.com

Medicenna Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 37th Annual Meeting

September 28, 2022 | finance.yahoo.com

Medicenna Reports Confirmed Partial Response in Pancreatic Cancer and Clinical Update on MDNA11’s Monotherapy Dose Escalation Portion of the Ongoing Phase 1/2 ABILITY Study

September 13, 2022 | finance.yahoo.com

Medicenna Announces Clinical Collaboration with Merck to evaluate MDNA11 in combination with KEYTRUDA® (pembrolizumab) in ABILITY Trial

September 8, 2022 | finance.yahoo.com

Medicenna to Present at Investor and Scientific Conferences in September

August 23, 2022 | finance.yahoo.com

MDNA: Awaiting Scan Results for Unconfirmed Partial Response in ABILITY Trial…

August 15, 2022 | finance.yahoo.com

Medicenna Reports First Quarter Fiscal 2023 Financial Results and Operational Highlights

August 11, 2022 | finance.yahoo.com

Medicenna Announces Closing of Public Offering of Units Raising US$20 Million to Advance Pipeline

August 8, 2022 | finance.yahoo.com

Medicenna Announces the Launch of a Marketed Underwritten Public Offering of Units

June 9, 2022 | finance.yahoo.com

Medicenna Strengthens Intellectual Property Protection for Superkine Platform with Issuance of U.S. Patent

May 10, 2022 | finance.yahoo.com

Will Medicenna Therapeutics (TSE:MDNA) Spend Its Cash Wisely?

May 3, 2022 | seekingalpha.com

CIG, GRTX and MDNA among pre market gainers

April 27, 2022 | msn.com

MDNA: AACR Presentations Highlight Preclinical Data for Anti-PD1-IL-2 BiSKIT and IL-13 Super-Antagonist…

March 9, 2022 | finance.yahoo.com

Medicenna Announces Upcoming Poster Presentations at the AACR Annual Meeting

See More Headlines

MDNA Price History

30 days | 90 days | 365 days | Advanced Chart

Industry, Sector and Symbol

Stock Exchange: TSE
Industry: Biotechnology
Sub-Industry: N/A
Sector: Medical
Current Symbol: TSE:MDNA
CUSIP: N/A
CIK: N/A
Web: www.medicenna.com
Phone: +1-403-6807898
Fax: N/A
Employees: 13
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: C$5.33
High Stock Price Forecast: C$9.00
Low Stock Price Forecast: C$2.00
Forecasted Upside/Downside: +592.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): C($0.16)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: C$-9,400,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -32.99%
Return on Assets: -33.27%

Debt

Debt-to-Equity Ratio: 0.06
Current Ratio: 7.70
Quick Ratio: 4.65

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: C$0.67 per share
Price / Cash Flow: 1.15
Book Value: C$0.48 per share
Price / Book: 1.60

Miscellaneous

Outstanding Shares: 69,640,000
Free Float: N/A
Market Cap: C$53.62 million
Optionable: Not Optionable
Beta: 0.53

Key Executives

Dr. Fahar Merchant Ph.D. (Age 65)
Founder, Chairman, Pres & CEO
Comp: $462.15k

Ms. Rosemina Merchant B.Sc. (Age 65)
M.E.Sc, Founder, Chief Devel. Officer & Director
Comp: $370.62k

Ms. Elizabeth Williams C.A. (Age 44)
CPA, CA, CPA, CFO & Corp. Sec.
Comp: $311k

Dr. Martin Bexon M.D.
MBBS, Acting Chief Medical Officer & Head of Clinical Devel.

Dr. Samuel R. Denmeade M.D.
Scientific Advisor

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

MDNA Stock - Frequently Asked Questions

Should I buy or sell Medicenna Therapeutics stock right now?: 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Medicenna Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MDNA shares.
View MDNA analyst ratings or view top-rated stocks.
What is Medicenna Therapeutics' stock price forecast for 2023?: 5 equities research analysts have issued 12-month price objectives for Medicenna Therapeutics' shares. Their MDNA share price forecasts range from C$2.00 to C$9.00. On average, they anticipate the company's stock price to reach C$5.33 in the next twelve months. This suggests a possible upside of 592.6% from the stock's current price.
View analysts price targets for MDNA or view top-rated stocks among Wall Street analysts.
How have MDNA shares performed in 2023?: Medicenna Therapeutics' stock was trading at C$0.64 at the beginning of 2023. Since then, MDNA stock has increased by 20.3% and is now trading at C$0.77.
View the best growth stocks for 2023 here.
What other stocks do shareholders of Medicenna Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Medicenna Therapeutics investors own include OPKO Health (OPK), AbbVie (ABBV), Livongo Health (LVGO), Aptose Biosciences (APTO), Birchcliff Energy (BIR), CVS Health (CVS), Freehold Royalties (FRU), Fastly (FSLY) and Inovio Pharmaceuticals (INO).

What is Medicenna Therapeutics' stock symbol?: Medicenna Therapeutics trades on the Toronto Stock Exchange (TSX) under the ticker symbol "MDNA."
How do I buy shares of Medicenna Therapeutics?: Shares of MDNA stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.
What is Medicenna Therapeutics' stock price today?: One share of MDNA stock can currently be purchased for approximately C$0.77.
How much money does Medicenna Therapeutics make?: Medicenna Therapeutics (TSE:MDNA) has a market capitalization of C$53.62 million. The company earns C$-9,400,000.00 in net income (profit) each year or C($0.16) on an earnings per share basis.
How can I contact Medicenna Therapeutics?: Medicenna Therapeutics' mailing address is 2440 Kensington Rd NW, CALGARY, AB T2N 3S1, Canada. The official website for the company is www.medicenna.com. The company can be reached via phone at +1-403-6807898.

This page (TSE:MDNA) was last updated on 6/8/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial